Only a handful of players could establish a stronghold in the global hospital acquired pneumonia drugs market. Fierce competition exists between them and to gain an edge over rivals, these companies often resort to strategic mergers, states Transparency Market Research (TMR) in a new report. The dominant players in the market are constantly competing for the acquisition of the product pipeline, which holds promise for most profit across diverse therapeutic areas.
Zosyn, a drug manufactured by Pfizer in 1996 is one of the most popular drugs in the market administered in the treatment of hospital acquired pneumonia. Zyvox, another drug created by Pfizer earned a revenue of US$1.3 bn in 2013. Recently, Pfizer and Teva Pharmaceuticals have agreed to a licensing deal as per which the latter is given the right to commercialize generic linezolid injections. Besides these enterprises, Durata Therapeutics, Cunicin, and Merck also hold a strong position in hospital acquired pneumonia drugs pipeline.
According to TMR, six drugs in phase III is projected to cumulatively generate about US$3.8 bn by the end of 2020. Among the phase III candidates, ceftolozane/tazobactam is expected to hold the dominant market share of 23% by value, before 2020 ends.
Demand for Medications to Rise in Developing Countries Due to High Prevalence of Disease
According to a report published by the World Health Organization (WHO), the prevalence of nosocomial or hospital acquired infection is approximately 7.1% in European countries as against 4.5% in the U.S. The number however shoots rapidly in case of developing nations, which reported a sizeable 19.1% prevalence of nosocomial infections. Due to such high prevalence, the demand for hospital acquired pneumonia drugs is expected to remain high across the developing economies of Asia Pacific.
With Drug Resistance Reaching Crisis Levels, Hospital Acquired Pneumonia Drugs Pipeline Expected to Gain Momentum
According to an article published by Los Angeles Biomedical Research Institute in their journal, titled Antimicrobial Agents and Chemo, drug resistance among patients of hospital acquired infections has reached crisis levels. This article contains results shows increasing resistance to conventional drugs. Hence the growth of the microorganisms that leads to infections such as pneumonia in hospital premises is increasing. The situation demands effective medications, thus boosting prospects for the hospital acquired pneumonia drug pipeline.
Inefficient sterilization and unhygienic hospital conditions across middle and low-income countries are increasing the prevalence of hospital acquired infections. This is also creating considerable growth opportunities for the market.
Stringent Government Policies Could Inhibit Market’s Growth
On the flip side, several stringent policies adopted by governments are acting as restraints for the market. The Centers of Medicare and Medicaid Services announced its plans to reduce medical reimbursements in 2014. Furthermore, a new program launched by federal agency called Hospital Acquired Conditions (HAC) Reduction Program, grades hospitals on the basis of patient safety. With governments around the world toughening their stands with regards to scrutinizing hospitals, the hospital acquired pneumonia drugs pipeline will have to cater to various regulations before the final approval. This may inhibit the market’s growth to an extent.
Nevertheless, the TMR report forecasts promising future for vaccines in the hospital acquired pneumonia market. Furthermore, potential for research in vaccine development for causative agents besides S. pneumonia also holds significant opportunities for the market’s growth in the near future.
This review is based on information published by TMR in a report, titled “Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020.”
The report segments the global hospital acquired pneumonia drugs pipeline as:
Global Hospital Acquired Pneumonia Drug Pipeline, Late Stage Candidates (Phase III)
- Tedizolid phosphate
- Amikacin inhale
Global Hospital Acquired Pneumonia Drug Pipeline, Early Stage Candidates (Phase II, Phase I and Preclinical Trials)
- AR-101 or KBPA101
- GSK 2189242A
- AR 301 or KBSA301
- AR-104 or KBPA104
- AR-201 or KBRV201
- AR-401 or KBAB401
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453